ESTC vs TDC vs XTLB Stock Comparison

Elastic, Teradata and Xtl Biopharmaceuticals Prices as of Oct 27, 2026 Peers: Industry group
ESTC Elastic N.V.
$105.51 +19.9% 1M +19.0% 1Y
Market cap
$11.09B
P/E
29.4x
Revenue (TTM)
$1.80B
Div. yield
–
Data Infrastructure Technology
3 wins
TDC Teradata Corp /De/
$34.53 +19.3% 1M +61.6% 1Y
Market cap
$3.21B
P/E
7.1x
Revenue (TTM)
$1.69B
Div. yield
–
Data Infrastructure Technology
7 wins

Head to Head

10 decided of 12

Teradata leads on 7 of the 12 questions below (Teradata 7, Elastic 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionESTCTDCXTLBLeader
Larger companyMarket capitalisation $11.09B $3.21B $17.13M ESTC
Cheaper on earningsLower P/E, profitable companies only 29.4x 7.1x -2.3x TDC
Cheaper on forward earningsLower price / next fiscal year consensus EPS 30.1x 13.3x — TDC
Faster revenue growthRevenue growth, trailing twelve months +16.2% +1.0% — ESTC
More profitableNet margin, trailing twelve months 20.8% 27.1% — TDC
Better return on capitalReturn on invested capital 0.0% 12.3% — TDC
Less leveragedLower net debt / EBITDA -10.8x — — –
Higher dividend yieldTrailing dividend yield — 0.00% — –
Better 1-year returnPrice return, last 12 months +19.0% +61.6% -62.3% TDC
Better 5-year returnAnnualised price return, 5 years -9.3%/yr -9.3%/yr -34.7%/yr TDC
Less volatileAnnualised volatility, 1 year 58.1% 64.4% 108.7% ESTC
Higher overall scoreMean of the five percentile scores vs peers 71/100 79/100 — TDC

Percentile Scorecard

ESTCTDCXTLB

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisESTCTDCXTLB
Valuation 70 #38 of 124 98 #3 of 124 24 #476 of 625
Growth 81 #22 of 113 71 #33 of 113 –
Profitability 67 #37 of 109 96 #5 of 109 –
Financial Health 52 #61 of 127 36 #82 of 127 2 #642 of 656
Shareholder Returns 86 #10 of 65 92 #6 of 65 –
Overall 71 79 –
  • ESTC ranked among 137 companies in Infrastructure Software
  • TDC ranked among 137 companies in Infrastructure Software
  • XTLB ranked among 672 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodESTCTDCXTLBSPY
1 month +19.9%+19.3%-19.6% -0.2%
3 months +70.0%+18.2%-39.1% +3.9%
6 months +122.4%+33.9%-21.3% +8.2%
Year to date +39.9%+13.4%-22.0% +12.9%
1 year +19.0%+61.6%-62.3% +12.3%
3 years +39.7%-18.2%-44.8% +87.4%
3 years, per year +11.8%-6.5%-18.0% +23.3%
5 years -38.5%-38.5%-88.1% +67.9%
5 years, per year -9.3%-9.3%-34.7% +10.9%
10 years —+24.8%-89.6% +261.1%
10 years, per year —+2.2%-20.3% +13.7%

Risk

MeasureESTCTDCXTLBSPY
Volatility, 1Y 58.1%64.4%108.7% 12.7%
Downside volatility, 1Y 59.1%58.7%90.3% 12.7%
Beta vs S&P 500, 1Y 1.141.170.54 1.00
Return / volatility, 1Y 0.330.96-0.57 0.97
Max drawdown, 5Y -76.8%-66.6%-88.9% -25.4%
From 52-week high -0.7%-8.8%-62.3% -1.2%
52-week high $106.26$37.88$4.80 $779.14
52-week low $43.30$20.71$1.78 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleESTCTDCXTLB
P/E now vs peer median 29.4xmedian 38.6x 7.1xmedian 38.6x -2.3xmedian 17.2x
P/S now vs peer median 6.2xmedian 4.4x 1.9xmedian 4.4x 2,447xmedian 9.0x
EV/EBITDA now vs peer median 123.3xmedian 34.5x 12.6xmedian 34.5x —median 16.3x
P/FCF now vs peer median 31.8xmedian 29.4x 4.4xmedian 29.4x -16.7xmedian 18.7x
P/B now vs peer median 8.6xmedian 3.3x 5.4xmedian 3.3x -67.4xmedian 2.2x
PEG now vs peer median 0.55median 1.28 0.07median 1.28 —median 0.33

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsESTCTDCXTLB
Revenue $1.80B $1.69B –
Gross profit $1.36B $1.03B –
Operating income -$47.61M $127.00M –
Net income $375.64M $458.00M –
Free cash flow $349.04M $736.00M –
R&D $455.30M $290.00M –
EPS (diluted) $3.59 $4.76 –
Cash & equivalents $879.87M $414.00M $76.00K
Total debt $571.20M – $530.00K
Shares (diluted) 104.64M 96.20M 8.96M
Enterprise value $5.62B $1.08B $13.93M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricESTCTDCXTLB
P/E 29.4x 7.1x -2.3x
P/FCF 31.8x 4.4x -16.7x
P/Operating cash flow 31.3x 4.2x –
P/S 6.2x 1.9x 2,447x
P/B 8.6x 5.4x -67.4x
P/Tangible book 8.6x 5.8x -67.4x
EV/EBITDA 123.3x 12.6x –
EV/EBIT -214.3x 22.0x –
EV/Revenue 5.7x 1.7x –
EV/FCF 29.2x 3.8x –
EV/Operating cash flow 28.8x 3.7x –
PEG (3Y EPS CAGR) 0.55 0.07 –

Growth

14 metrics
MetricESTCTDCXTLB
Revenue growth (1Y) 16.2% 1.0% –
Revenue CAGR (3Y) 17.4% -2.2% –
Gross profit growth (1Y) 16.7% 4.2% –
Gross profit CAGR (3Y) 18.8% -2.2% –
Operating income growth (1Y) -56.0% -31.4% –
Operating income CAGR (3Y) 37.5% -5.0% –
Net income growth (1Y) 549.9% 316.4% –
Net income CAGR (3Y) 55.3% 99.1% –
EPS growth (1Y) 555.6% 315.5% –
EPS CAGR (3Y) 53.7% 103.7% –
Operating cash flow growth (1Y) 11.3% 168.0% –
Operating cash flow CAGR (3Y) 62.1% 33.3% –
Free cash flow growth (1Y) 11.2% 178.8% –
Free cash flow CAGR (3Y) 63.2% 34.3% –

Profitability

14 metrics
MetricESTCTDCXTLB
Gross margin 75.5% 60.8% –
EBITDA margin 4.6% 13.1% –
Operating margin -2.6% 7.5% –
Pretax margin -1.1% 34.9% –
Net margin 20.8% 27.1% –
FCF margin 19.4% 43.5% –
Operating cash flow margin 19.6% 45.0% –
Return on equity 29.2% 79.7% –
Return on assets 12.2% 24.1% –
Return on invested capital 0.0% 12.3% –
Return on capital employed -2.3% 12.0% –
Asset turnover 0.6x 0.9x –
Cash conversion (OCF / net income) 0.9x 1.7x –
Stock comp / revenue 16.8% 7.2% –

Financial Health

11 metrics
MetricESTCTDCXTLB
Debt / assets 19.0% – 83.1%
Debt / equity 0.4x – -0.5x
Net debt / EBITDA -10.8x – –
Debt / FCF 1.6x – –
Liabilities / assets 56.8% 64.2% 253.0%
Equity / assets 43.2% 35.8% -153.0%
Interest coverage -1.9x 5.1x –
Current ratio 1.8x 0.9x 0.4x
Quick ratio 1.6x 0.8x 0.4x
Cash ratio 1.4x 0.5x 0.2x
Altman Z-score 4.44 1.66 –

Shareholder Returns

7 metrics
MetricESTCTDCXTLB
Dividend yield – – –
Net buyback yield 3.1% 4.4% –
Shareholder yield 3.1% 4.4% –
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusESTCTDCXTLB
Forward P/E 30.1xFY2026 13.3xFY2026 –
EPS, next fiscal year $3.51FY2026 $2.59FY2026 –
EPS growth, next FY +36.6%FY2026 +0.4%FY2026 –
EPS growth, the year after +19.4% +17.4% –
Revenue, next fiscal year $1.88BFY2026 $1.56BFY2026 –
Revenue growth, next FY +8.2%FY2026 -5.8%FY2026 –
Revenue growth, the year after +18.3% +9.4% –

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersESTCTDCXTLB
Held by institutions 86.4% 100.0% –
Institutions holding 371 475 –
Change in shares held, QoQ +1.7% +12.1% –
Institutions buying 199 279 –
Institutions selling 129 121 –
Buyers to sellers 1.54 2.31 –

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ESTCTDCXTLB
ESTC 1.00 0.31 0.00
TDC 0.31 1.00 0.06
XTLB 0.00 0.06 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ESTC, TDC and XTLB?

Elastic (ESTC) is the largest by market capitalisation: Elastic (ESTC) $11.09B, Teradata (TDC) $3.21B, Xtl Biopharmaceuticals (XTLB) $17.13M.

Which stock is cheaper, ESTC, TDC and XTLB?

Teradata (TDC) trades on the lowest price-to-earnings ratio (Elastic (ESTC) 29.4x, Teradata (TDC) 7.1x, Xtl Biopharmaceuticals (XTLB) -2.3x). On next year's consensus earnings, Teradata (TDC) is cheapest (Elastic (ESTC) 30.1x, Teradata (TDC) 13.3x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Elastic (ESTC) grew revenue fastest over the trailing twelve months: Elastic (ESTC) +16.2%, Teradata (TDC) +1.0%.

Which company is more profitable?

Teradata (TDC) has the highest net margin (Elastic (ESTC) 20.8%, Teradata (TDC) 27.1%). On return on invested capital, Teradata (TDC) leads (Elastic (ESTC) 0.0%, Teradata (TDC) 12.3%).

Which stock has performed better?

Over the past year Teradata (TDC) returned the most: Elastic (ESTC) +19.0%, Teradata (TDC) +61.6%, Xtl Biopharmaceuticals (XTLB) -62.3%. Over five years, Teradata (TDC) compounded fastest (Elastic (ESTC) -9.3%/yr, Teradata (TDC) -9.3%/yr, Xtl Biopharmaceuticals (XTLB) -34.7%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Elastic (ESTC) has been the steadiest (Elastic (ESTC) 58.1%, Teradata (TDC) 64.4%, Xtl Biopharmaceuticals (XTLB) 108.7%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ESTC, TDC and XTLB?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Teradata (TDC) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.